Matogen Applied InsightsMatogen Applied InsightsMatogen Applied InsightsMatogen Applied Insights
  • Home
    Landing Page
  • Our Work
    Company Portfolio
    • Capabilities
    • Insights
    • Industries
      • Fintech
      • Healthcare
      • Agriculture
    • Testimonials
  • Capabilities
    Our Expertise
  • Get in Touch
    Contact Us
  • Our Partners
    Work with the best
    • Databricks
    • Praexia
  • About Us
    Who We Are
    • Mission & Vision
    • History
    • Our Team

Oncology Data Modelling

    Home Insights Oncology Data Modelling
    oncology-data

    Oncology Data Modelling

    By Ibtisaam | Insights, Health | 0 comment | 5 October, 2020 | 0

    In one of many health sector Big Data projects, Matogen Applied Insights (MAI) performed oncology data modelling for an international client.

    Big Data in healthcare

    The benefits and prevalence of Big Data in the healthcare sector are well-known, but it  has been said that Big Data analytics can be considered a potential game-changer in the fight against cancer in particular. Previously, medical researchers had to rely on small sample sizes, case studies and relatively sparse tumour DNA or genetic analyses. 

    In contrast, the current availability of enormous publicly available databases containing a mind-boggling range of data on different types of cancers, across a spectrum of demographics, regions and genetic profiles, have rendered traditional analytics tools defunct. The advanced computer modelling and wrangling provided by data scientists make it possible to construct better predictive models for improved diagnosis and tailor-made treatment.

    Oncological data modelling 

    In this project, oncological data was extracted from a large, publicly available, all-payer, inpatient healthcare database designed to produce regional and national estimates of inpatient utilisation, access, charges, quality, and outcomes for the United States.

    The oncological data modelling determined which outcome was most probable in patients (based on their attributes) with breast cancer and what route of intervention to follow based on the result. For example, this aided oncologists in deciding whether to administer neoadjuvant chemotherapy or perform invasive surgery on the patient before administering chemo.

    This study also interrogated the possibility of predicting the downstaging of a tumour and the level of lymphovascular invasion after neoadjuvant chemotherapy.

    No tags.

    Potchefstroom (ZA)

    2 Makou Street,
    Potchefstroom
    2531

    info@ai.matogen.com
    • Home
      Landing Page
    • Our Work
      Company Portfolio
      • Capabilities
      • Insights
      • Industries
        • Fintech
        • Healthcare
        • Agriculture
      • Testimonials
    • Capabilities
      Our Expertise
    • Get in Touch
      Contact Us
    • Our Partners
      Work with the best
      • Databricks
      • Praexia
    • About Us
      Who We Are
      • Mission & Vision
      • History
      • Our Team
    Matogen Applied Insights